Medicxi

Francesco De Rubertis pioneered an asset-centric biotech model that builds companies around a few drug assets and scaled it by assembling Centessa Pharmaceuticals as a company-of-companies aggregating asset-centric subsidiaries.

Giovanni Mariggi co-founded a biotech venture firm after pioneering asset‑centric investing—concentrating teams around single high‑conviction drug assets—and takes a hands‑on vaccine company‑building role, chairing ViceBio and serving on Curevo's board.

Co-founder and Partner at Medicxi, where he leads finance, capital raising, and investor relations. He previously held senior roles at Index Ventures and Intermediate Capital Group, and began his career at PwC in Auckland as a Chartered Accountant.

Co-founder and Senior Advisor at Medicxi who previously co-founded Index Ventures in 1996 and helped launch its first growth fund in 2007, later playing a key role in launching Medicxi's first growth fund in 2016. Earlier he spent five years as a consultant at McKinsey.

Co-founder and Senior Advisor at Medicxi who previously spent 13 years as a Partner at Index Ventures, where he originated its first asset-centric investment and led Medicxi's investment in Impact Biomedicines. Earlier he was Research Director and CTO at Cambridge Antibody Technology, contributing to antibodies now marketed as Humira and Benlysta.

Co-founder and Senior Advisor at Medicxi who previously spent a decade as a Partner at Index Ventures and earlier served as Investment Director at Edmond de Rothschild Investment Partners in Paris. She has led numerous biopharma investments and spent over 15 years in development and marketing roles across Sanofi, BMS, Aventis and Serono, and holds a medical degree.

Co-founder and Operating Partner at Medicxi, overseeing firm operations and serving as General Counsel. Previously worked at Index Ventures advising on US and European life sciences and technology investments, and was a corporate associate at Linklaters.

Nick Williams is an asset-centric venture partner who leads a €500m fund, backing single-disease biotech companies aimed at pharma acquisition and known for patient-focused, influential commentary on European biotech financing.

Shyam Masrani is a former biotech founder (two companies) and ADC/complex oncology platform specialist who led investments like Merus, serves on multiple biotech boards and is a recognized ADC expert.

Victoria Taylor, an Oxford MBiochem scientist-turned-investor, co-founded biotech startups Imhotex, Perfect Balance and Pandeia Therapeutics and brings company-creation and operations experience from the Foundation Institute for 21st Century Medicine.

Ben Perry spent two decades in drug discovery at DNDi, Addex and UCB, co-founded AiDD SA and MPC Therapeutics SA, and maintains active publications and deep medicinal chemistry expertise.

Charles Grummitt's Cambridge PhD in Protein Engineering plus hands-on experience building antibody discovery platforms at F-star and Adaptimmune makes him relevant to founders developing complex biologics and next-generation antibody formats.

João Vieira offers two decades of antibody engineering and protein therapeutics R&D plus discovery leadership at argenx, serving as a hands-on scientific co‑architect from concept to clinical-stage for antibody/protein opportunities.

Marco Prunotto brings hands-on bench-to-bedside experience from leading Roche's phenotypic drug discovery, nephrology and translational research teams, while serving as Full Professor and teaching scientists VC evaluation of translational value.

Mehdi Shahidi pairs deep hands-on development and regulatory expertise—overseeing first-in-human transitions for 30+ NMEs and global approvals at Boehringer Ingelberg—with active leadership roles, making him an embedded R&D partner.

Venture Partner at Medicxi supporting portfolio companies such as Curevo and Altesa Biosciences (and previously ViceBio, acquired by Sanofi). He formerly served as Chief Scientific Advisor to Operation Warp Speed and spent nearly 30 years at GlaxoSmithKline in senior R&D and vaccines leadership roles. He holds a PhD in Molecular Biology and Immunology from the Universite Libre de Bruxelles and has served on numerous biotech boards including Moderna, Vaxcyte, Arcturus Therapeutics and Zephyr AI.

Stephen Rapecki originated the blockbuster biologic bimekizumab from discovery to approval, combining 30 years of hands-on drug discovery at Celltech/UCB with ongoing peer-reviewed immunology research and seed-stage cofounding and advising.

Thibaut De Smedt is a former Amgen and Addex R&D scientist who brings a drug-discovery–first, deeply technical approach, serial company founding experience and hands-on managing-director roles in portfolio companies.

Joined Burda in 2022 and is an Investment Manager in the Singapore office. Previously spent two and a half years at SeaMoney, the fintech arm of Sea Group. A CFA charterholder.

Andrew Jeanne handles day-to-day fund administration at Medicxi. He previously was a Manager at Intertrust Fund Services with over ten years of experience in private equity and venture capital fund administration and governance, and holds an LLB (hons) Law Degree from Coventry University.

Associate at Medicxi who previously worked at L.E.K Consulting advising global pharmaceutical and biotech companies on corporate, clinical development and commercialisation strategy. Holds a medical degree from the University of Sheffield and a BSc in Medical Sciences from Imperial College London.

Associate at Medicxi who previously worked on Temasek's Healthcare and Life Sciences direct investment team covering public and private deals across EMEA, and earlier was a Marie Sklodowska-Curie Postdoctoral Research Fellow at the VIB-UGent Center for Inflammation Research. She holds a BSc in Biological Sciences (Immunology) from Edinburgh, a PhD in Immunology from Manchester, and an MBA from London Business School.

Giles Johnstone-Scott oversees Medicxi's Jersey operations and group compliance. He previously served as a Director at Intertrust Fund Services (formerly Elian Fund Services) and has over 15 years of experience in Jersey's financial services industry.

Marie Beaucourt is Medicxi's Office & Travel Manager and provides executive support to Francesco De Rubertis, handling logistics for the Medicxi Forum and Scientific Advisory Board meetings. She previously spent four years at Index Ventures starting in 2012 and holds an MBA in International Travel Management.

Natalie is a financial accountant on the Medicxi operations team. She previously worked as an accountant at VG and as an assistant accountant at Intertrust Fund Services.

Nina Moir is Medicxi's Office and HR Manager. She previously spent 11 years at Index Ventures (from 2005) and earlier worked at The National Magazine Company (now Hearst) as Office Manager for the IT department.

Philip Brown is Finance Manager in Medicxi's operations team, previously a client accountant at Intertrust Fund Services and Stonehenge Fleming Corporate Services with over a decade in Channel Islands financial services. He holds a BA (Hons) in Accounting and Finance from the University of Northumbria and is a member of the Chartered Institute of Management Accountants.

Venture Advisor and co-founding team member at Medicxi who has supported the development of several Index Ventures and Medicxi portfolio companies. He is Chairman, CEO and Chief Scientific Officer of Minerva Neurosciences and was previously President and CEO of the Forenap Group; he holds PhDs in Neurosciences and Clinical Pharmacology from the University of Strasbourg.

Sylvia Elder is Deputy General Counsel at Medicxi, advising on seed, venture and growth-stage investment transactions, compliance and corporate matters. She previously trained and worked as a corporate associate at Nabarro LLP (now CMS), handling M&A, IPOs and investment deals in tech and biotech, including a secondment at GlaxoSmithKline.

Venture Advisor at Medicxi who is involved with several portfolio companies, including serving as COO of Alys Pharmaceuticals. He spent 24 years at Galderma in roles such as Global Head of Research and Global Head of Development Strategy, later leading its Prescription Medicines Global Business Unit; he holds a PhD in Medicinal Chemistry from Wayne State University.

A clinician and drug-discovery specialist who co-founded Apcintex (acquired by Centessa Pharmaceuticals) and XO1 (acquired by Janssen), and chairs the Scientific Advisory Board of Vaderis Therapeutics. He previously practiced at Cambridge University Hospitals as Director of Investigative Sciences, focusing on thrombosis and blood coagulation research, and led several haematology societies.